Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 392024, 8 pages
http://dx.doi.org/10.1155/2013/392024
Research Article

Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies

1Department of Nursing, Mackay Medical College, New Taipei City 25245, Taiwan
2Institute of Clinical and Community Health Nursing, National Yang-Ming University, Taipei 11221, Taiwan
3Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
4Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan
5Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 11217, Taiwan
6Department of Surgery, National Yang-Ming University, Taipei 11221, Taiwan
7Department of Traditional Chinese Medicine, Taipei Medical University Hospital, Taipei 11031, Taiwan
8Department of OB/GYN, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

Received 24 December 2012; Revised 23 February 2013; Accepted 24 February 2013

Academic Editor: Zhaoxiang Bian

Copyright © 2013 Sheng-Miauh Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. B. Su, A. Lu, S. Li, and W. Jia, “Evidence-based ZHENG: a traditional Chinese medicine syndrome,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 246538, 2 pages, 2012. View at Publisher · View at Google Scholar
  2. A. S. Ferreira and A. J. Lopes, “Chinese medicine pattern differentiation and its implications for clinical practice,” Chinese Journal of Integrative Medicine, vol. 17, no. 11, pp. 818–823, 2011. View at Publisher · View at Google Scholar
  3. A. P. Lu and K. J. Chen, “Integrative medicine in clinical practice: from pattern differentiation in traditional Chinese medicine to disease treatment,” Chinese Journal of Integrative Medicine, vol. 15, no. 2, p. 152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. World Health Organization, WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region, WHO, Geneva, Switzerland, 2007.
  5. H. M. Langevin, G. J. Badger, B. K. Povolny et al., “Yin scores and Yang scores: a new method for quantitative diagnostic evaluation in traditional Chinese medicine research,” Journal of Alternative and Complementary Medicine, vol. 10, no. 2, pp. 389–395, 2004. View at Google Scholar · View at Scopus
  6. C. L. Hsieh, S. F. Kuo, Q. Y. Chang, and C. L. Lu, “Pattern identification of Qi deficiency and blood stasis in cancer patients,” Mid-Taiwan Journal of Medicine, vol. 12, no. 2, pp. 109–116, 2007. View at Google Scholar · View at Scopus
  7. C. A. Berle, D. Cobbin, N. Smith, and C. Zaslawski, “A novel approach to evaluate traditional Chinese medicine treatment outcomes using pattern identification,” Journal of Alternative and Complementary Medicine, vol. 16, no. 4, pp. 357–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Jiang, C. Zhang, G. Zheng et al., “Traditional Chinese medicine Zheng in the era of evidence-based medicine: a literature analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 409568, 9 pages, 2012. View at Publisher · View at Google Scholar
  9. Department of Health, Executive Yuan, Taiwan, The Mortality of Cancer in Taiwan, 2012, http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=12336&class_no=440&level_no=4.
  10. U. S. Cancer Statistics Working Group, Centers for Disease Control and Prevention and National Cancer Institute, and U.S. Department of Health and Human Services, Atlanta, United States Cancer Statistics: 2004–2008 Incidence and Mortality Web-Based Report, 2012, http://apps.nccd.cdc.gov/uscs/.
  11. L. Gianni, U. Dafni, R. D. Gelber et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, no. 9555, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Spichiger, C. Müller-Frِhlich, K. Denhaerynck, H. Stoll, V. Hantikainen, and M. Dodd, “Prevalence of symptoms, with a focus on fatigue, and changes of symptoms over three months in outpatients receiving cancer chemotherapy,” Swiss Medical Weekly, vol. 141, Article ID w13303, 2011. View at Publisher · View at Google Scholar
  14. N. K. Janz, M. Mujahid, L. K. Chung et al., “Symptom experience and quality of life of women following breast cancer treatment,” Journal of Women’s Health, vol. 16, no. 9, pp. 1348–1361, 2007. View at Publisher · View at Google Scholar
  15. P. A. Ganz, L. Kwan, A. L. Stanton, J. E. Bower, and T. R. Belin, “Physical and psychosocial recovery in the year after primary treatment of breast cancer,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1101–1109, 2011. View at Publisher · View at Google Scholar
  16. H. Sawaya, I. A. Sebag, J. C. Plana et al., “Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab,” Circulation, Cardiovascular Imaging, vol. 5, no. 5, pp. 596–603, 2012. View at Google Scholar
  17. G. Piotrowski, R. Gawor, A. Stasiak, Z. Gawor, P. Potemski, and M. Banach, “Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2—a prospective study,” Archives Medical Science, vol. 8, no. 2, pp. 227–235, 2012. View at Google Scholar
  18. Z. Chen and P. Wang, “Clinical distribution and molecular basis of traditional Chinese medicine ZHENG in cancer,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 783923, 8 pages, 2012. View at Publisher · View at Google Scholar
  19. Z. Chen, L. Y. Chen, P. Wang, H. Y. Dai, S. Gao, and K. Wang, “Tumor microenvironment varies under different TCM ZHENG models and correlates with treatment response to herbal medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 635702, 10 pages, 2012. View at Publisher · View at Google Scholar
  20. K. Arthur, J. C. Belliard, S. B. Hardin, K. Knecht, C. S. Chen, and S. Montgomery, “Practices, attitudes, and beliefs associated with complementary and alternative medicine (CAM) use among cancer patients,” Integrative Cancer Therapies, vol. 11, no. 3, pp. 232–242, 2012. View at Publisher · View at Google Scholar
  21. M. Horneber, G. Bueschel, G. Dennert, D. Less, E. Ritter, and M. Zwahlen, “How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis,” Integrative Cancer Therapies, vol. 11, no. 3, pp. 187–203, 2012. View at Publisher · View at Google Scholar
  22. C. R. Chien, S. Y. Su, L. Cohen, H. W. Lin, R. T. Lee, and Y. C. Shih, “Use of Chinese medicine among survivors of nasopharyngeal carcinoma in Taiwan: a population-based study,” Integrative Cancer Therapies, vol. 11, no. 3, pp. 221–231, 2012. View at Publisher · View at Google Scholar
  23. J. N. Lai, C. T. Wu, and J. D. Wang, “Prescription pattern of Chinese herbal products for breast cancer in Taiwan: a population-based study,” , Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 891893, 7 pages, 2012. View at Publisher · View at Google Scholar
  24. Y. H. Liao, C. C. Lin, T. C. Li, and J. G. Lin, “Utilization pattern of traditional Chinese medicine for liver cancer patients in Taiwan,” BMC Complementary and Alternative Medicine, vol. 2, no. 1, article 146, 2012. View at Google Scholar
  25. Y. C. Su, “The creation of traditional Chinese medical constitutional scale and classification index,” Yearbook of Chinese Medicine and Pharmacy, vol. 26, no. 5, pp. 65–152, 2008 (Chinese). View at Google Scholar
  26. L. L. Chen, J. D. Lin, Y. C. Huang, J. S. Lin, C. H. Huang, and Y. C. Su, “Scale descriptor selection for a Taiwan-version of a body constitution questionnaire in traditional Chinese medicine,” Mid-Taiwan Journal of Medicine, vol. 13, no. 1, pp. 35–42, 2008 (Chinese). View at Google Scholar · View at Scopus
  27. Y. C. Su, L. L. Chen, J. D. Lin, J. S. Lin, Y. C. Huang, and J. S. Lai, “BCQ+: a body constitution questionnaire to assess Yang-Xu—part I: establishment of a first final version through a Delphi process,” Forschende Komplementarmedizin, vol. 15, no. 6, pp. 327–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. L. L. Chen, J. S. Lin, J. D. Lin et al., “BCQ+: a body constitution questionnaire to assess Yang-Xu—part II: evaluation of reliability and validity,” Forschende Komplementarmedizin, vol. 16, no. 1, pp. 20–27, 2009. View at Publisher · View at Google Scholar
  29. J. Cheng, L. J. Edwards, M. M. Maldonado-Molina, K. A. Komro, and K. E. Muller, “Real longitudinal data analysis for real people: building a good enough mixed model,” Statistics in Medicine, vol. 29, no. 4, pp. 504–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Huang, L. Y. Chien, C. J. Tai, J. F. Chiou, C. S. Chen, and C. J. Tai, “Effectiveness of 3-week intervention of Shi Quan Da Bu Tang for alleviating hematotoxicity among patients with breast carcinoma receiving chemotherapy,” Integrative Cancer Therapies, 2012. View at Publisher · View at Google Scholar
  31. E. Jirkovsky, O. Popelova, P. Krivakova-Stankova et al., “Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on Nrf2 and mitochondrial biogenesis pathways,” Journal of Pharmacology and Experimental Therapeutics, vol. 343, no. 2, pp. 468–478, 2012. View at Publisher · View at Google Scholar